7MM Asthma Epidemiology Forecasts Research Report 2020-2034 with Real World Insights from KOLs and SMEs - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Asthma - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

The report delivers an in-depth understanding of the asthma, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by the Total Diagnosed Prevalent Cases of Asthma, Age-specific Diagnosed Prevalent Cases of Asthma, Gender-specific Diagnosed Prevalent Cases of Asthma, Severity-specific Diagnosed Prevalent Cases of Asthma, and Type-specific Diagnosed Prevalent Cases of Severe Asthma in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on asthma evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, along with challenges related to accessibility, including KOL from University of Michigan, US; Cincinnati Children's Hospital Medical Center, US; Pulmonary Department, Mainz University Hospital, Mainz, Germany; Department of Pharmacology, University Hospital Agostino Gemelli Foundation, Rome, Italy; Department of Respiratory Medicine, Queen Mary University of London, UK; Department of Respiratory Medicine and Clinical Immunology, Osaka University, Japan; and others.

The analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Key Highlights

• The analyst projects that among the total diagnosed prevalent cases of asthma in 7MM approximately 47% of cases were from the US in 2022. The increase in asthma cases is likely due to a combination of genetic predisposition, environmental factors like air pollution and allergens, changes in lifestyle, and improved awareness and diagnosis.
• In 2022, the adult population constituted 80% of total diagnosed asthma cases across the 7MM, reflecting the greater prevalence of asthma among adults due to factors such as prolonged exposure to environmental triggers and untreated childhood asthma persisting into adulthood.
• The projection that severity-specific intermittent asthma cases will surpass other categories by 2034 suggests a potential trend towards improved asthma management and prevention strategies, leading to fewer severe cases. This underscores the importance of early detection and targeted interventions to mitigate disease progression and reduce healthcare burden.
• As asthma prevalence evolves, understanding emerging environmental and genetic factors alongside advancements in medical interventions will be pivotal in shaping future prevalence rates and guiding effective prevention and management strategies.

Asthma Epidemiology

As per estimations, the total diagnosed prevalent cases of Asthma in the 7MM were around 54 million in 2022 and are projected to increase during the forecast period (2023-2034).

• There were approximately 26 million diagnosed prevalent cases of Asthma estimated to have occurred in the US in 2022. These cases are anticipated to grow in the foreseeable future during the study period.
• In 2022, EU4 and the UK accounted for nearly 25 million diagnosed prevalent population of asthma, projected to increase at a significant CAGR by 2034. Among EU4 and the UK, the UK accounted for the highest number of diagnosed asthma cases in 2022.
• Age-specific diagnosed prevalent cases of Asthma is categorized into pediatric and adults, with 5 million and about 20 million cases respectively in the US in 2022.
• The categorization based on gender, showed that diagnosed prevalent cases in female was higher than that in males. The female diagnosed prevalent cases accounted for 56% of the total cases in 2022.
• In the Japan, the intermittent, mild, moderate, and severe cases of asthma were over 2 million, 0.5 million, 0.8 million, and 0.6 million cases, respectively, in 2022.
• Type-specific diagnosed prevalent cases of Severe Asthma was segmented into type-2 inflammation and non-type-2 inflammation, among which the type-2 inflammation has a higher prevalence in 2022.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Asthma, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Asthma Report Insights

• Twelve Years Forecast of Asthma
• The 7MM Coverage
• Total Diagnosed Prevalent Cases Of Asthma
• Age-Specific Diagnosed Prevalent Cases Of Asthma
• Gender-Specific Diagnosed Prevalent Cases Of Asthma
• Severity-Specific Diagnosed Prevalent Cases Of Asthma
• Type-Specific Diagnosed Prevalent Cases Of Severe Asthma

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Methodology of Asthma Epidemiology

4. Executive Summary of Asthma

5. Key Events

6. Disease Background and Overview

6.1. Introduction of Asthma

6.2. Classification of Asthma

6.3. Signs and Symptoms of Asthma

6.4. Causes of Asthma

6.5. Pathophysiology of Asthma

6.6. Diagnosis of Asthma

6.6.1. Diagnostic algorithm

6.6.2. Diagnostic guidelines

6.6.2.1. NICE Recommendations for Asthma Diagnosis

6.6.2.2. British Guidelines on the Diagnosis of Asthma

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Assumptions and Rationale: The 7MM

7.2.1. Diagnosed prevalent cases of Asthma

7.2.2. Severity-specific cases of Asthma

7.2.3. Type-specific cases of severe Asthma

7.3. Total Diagnosed Prevalent Cases of Asthma in the 7MM

7.4. The United States

7.4.1. Total diagnosed prevalent cases of Asthma in the US

7.4.2. Age-specific diagnosed prevalent cases of Asthma in the US

7.4.3. Gender-specific diagnosed prevalent cases of Asthma in the US

7.4.4. Severity-specific diagnosed prevalent cases of Asthma in the US

7.4.5. Type-specific diagnosed prevalent cases of Severe Asthma in the US

7.5. EU4 and the UK

7.5.1. Germany

7.5.2. France

7.5.3. Italy

7.5.4. Spain

7.5.5. The UK

7.6. Japan

8. Patient Journey

9. KOL Views

10. SWOT Analysis

11. Unmet needs

12. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/s7s09i

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.